We used mass spectrometry to identify citrullinated peptides from the surfaceome and immunopeptidome of breast cancer cell lines and in the immunoglobulin-bound (IgB) fraction from TNBC patient plasma (Figure 1A) for vaccine development. Here, CD79B is linked to breast carcinoma.